Studies of binding modes of (S)-mephenytoin to wild types and mutants of cytochrome P450 2C19 and 2C9 using homology modeling and computational docking

Pharmaceutical Research

Volumn 21, Issue 12, 2004, Pages 2270-2278

  Oda, Akifumi ^a,b   Yamaotsu, Noriyuki ^b   Hirono, Shuichi ^b  

^a TOYAMA CHEMICAL CO LTD   (Japan)

^b KITASATO UNIVERSITY   (Japan)

Author keywords

Binding mode; Computational docking; Cytochrome P450 2C19; Homology modeling

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; MEPHENYTOIN;

ARTICLE; BINDING AFFINITY; CALCULATION; CRYSTAL STRUCTURE; DRUG BINDING; MUTANT; PRIORITY JOURNAL; PROTEIN STRUCTURE; REPRODUCIBILITY; SEQUENCE HOMOLOGY; WILD TYPE;

AMINO ACID SEQUENCE; ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BINDING SITES; MEPHENYTOIN; MIXED FUNCTION OXYGENASES; MOLECULAR SEQUENCE DATA; MUTATION; PROTEIN BINDING; RABBITS; SEQUENCE HOMOLOGY, AMINO ACID; STRUCTURAL HOMOLOGY, PROTEIN;

EID: 17644378105     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11095-004-7680-8     Document Type: Article

References (39)

1. M. Romkes, M. B. Faletto, J. A. Blaisdell, J. L. Raucy, and J. A. Goldstein. Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochemistry 30:3247-3255 (1991).
2. S. A. Wrighton, J. C. Stevens, G. W. Becker, and M. Vanden-Branden. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch. Biochem. Biophys. 306:240-245 (1993).
3. J. A. Goldstein, M. B. Faletto, M. Romkes-Sparks. T. Sullivan. S. Kitareewan, J. L. Raucy, J. M. Lasker, and B. I. Ghanayem. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 33:1743-1752 (1994).
4. A. Küpfer, P. Desmond, R. Patwardhan, S. Schenker, and R. A. Branch. Mephenytoin hydroxylation deficiency: kinetics after repeated doses. Clin. Pharmacol. Ther. 35:33-39 (1984).
5. S. M. F. de Morais, G. R. Wilkinson, J. Blaisdell, K. Nakamura, U. A. Meyer, and J. A. Goldstein. The major genetic defect responsible for the polymorphism of S-mephenytoin in humans. J. Biol. Chem. 269:15419-15422 (1994).
6. S. M. F. de Morais, G. R. Wilkinson, J. Blaisdell, K. Nakamura, U. A. Meyer, and J. A. Goldstein. Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin metabolism in Japanese. Mol. Pharmacol. 46:594-598 (1994).
7. Z. S. Xiao, J. A. Goldstein, H.-G. Xie, J. Blaisdell, W. Wang, C.-H. Jiang, F.-X. Yan, N. He, S.-L. Huang, Z.-H. Xu, and H.-H. Zhou. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J. Pharmacol. Exp. Ther. 281:604-609 (1997).
8. R. J. Ferguson, S. M. F. de Morais, S. Benhamou, C. Bouchardy, J. Blaisdell, G. Ibeanu, G. R. Wilkinson, T. C. Sarich, J. M. Wright, P. Dayer, and J. A. Goldstein. A novel defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J. Pharmacol. Exp. Ther. 284:356-361 (1998).
9. G. C. Ibeanu, J. A. Goldstein. U. Meyer, S. Benhamou, C. Bouchardy, P. Dayer, and B. I. Ghanayem. and J. Blaisdell. Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. J. Pharmacol. Exp. Ther. 286:1490-1495 (1998).
10. G. C. Ibeanu, J. Blaisdell, B. I. Ghanayem, C. Beyeler, S. Benhamou, C. Bouchardy, G. R. Wilkinson, P. Dayer, A. K. Daly, and J. A. Goldstein. An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Pharmacogenetics 8:129-135 (1998).
11. G. C. Ibeanu, J. Blaisdell, R. J. Gerguson, B. I. Ghanayem, K. Brosen, S. Benhamou, C. Bouchardy, G. R. Wilkinson, P. Dayer, and J. A. Goldstein. A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. J. Pharmacol. Exp. Ther. 290:635-640 (1999).
12. S. Kimura, J. Pastewka, H. V. Gelboin, and F. J. Gonzalez. cDNA and amino acid sequences of two members of the human P450IIC gene subfamily. Nucleic Acids Res. 15:10053-10054 (1987).
13. C.-C. Tsao, M. R. Wester, B. Ghanayem, S. J. Coulter, B. Chanas, E. F. Johnson, and J. A. Goldstein. Identification of human CYP2C19 residues that confer S-mephenytoin 4′-hydroxylation activity to CYP2C9. Biochemistry 40:1937-1944 (2001).
14. P. A. Williams, J. Cosme, V. Sridhar, E. F. Johnson, and D. E. McRee. Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. Mol. Cell 5:121-131 (2000).
15. R. D. Taylor, P. J. Jewsbury, and J. W. Essex. A review of protein-small molecule docking methods. J. Comput. Aided Mol. Des. 16:151-166 (2002).
16. M. Rarey, B. Kramer, T. Lengauer, and G. Klebe. A fast flexible docking method using an incremental construction algorithm. J. Mol. Biol. 261:470-489 (1996).
17. T. J. Ewing. DOCK 4.0: search strategies for automated molecular docking of flexible molecule databases. J. Comput. Aided Mol. Des. 15:411-428 (2001).
18. G. Jones, P. Willet, R. C. Glen, A. R. Leach, and R. Taylor. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 267:727-748 (1997).
19. D. F. V. Lewis, M. Dickins, R. J. Weaver, P. J. Eddershaw, P. S. Goldfarb, and M. H. Tarbit. Molecular modeling of human CYP2C subfamily enzymes CYP2C9 and CYP2C19: rationalization of substrate specificity and site-directed mutagenesis experiments in the CYP2C subfamily. Xenobiotica 28:235-268 (1998).
20. V. A. Payne, Y.-T. Chang, and G. H. Loew. Homology modeling and substrate binding study of human CYP2C18 and CYP2C19 enzymes. Proteins 37:204-217 (1999).
21. M. Ridderström, I. Zamora, O. Fjellström, and T. B. Andersson. Analysis of selective regions in the active sites of human cytochromes P450, 2C8, 2C9, 2C18 and 2C19 homology models using GRID/CPCA. J. Med. Chem. 44:4072-4081 (2001).
22. D. F. V. Lewis. Modeling human cytochromes P450 involved in drug metabolism from the CYP2C5 crystallographic template. J. Inorg. Biochem. 91:502-514 (2002).
23. M. J. de Groot, A. A. Alex, and B. C. Jones. Development of a combined protein and pharmacophore model for cytochrome P450 2C9. J. Med. Chem. 45:1983-1993 (2002).
24. K. Ogata and H. Umeyama. An automatic homology modeling method consisting of database searches and simulated annealing. J. Mol. Graphics Mod. 18:258-272 (2000).
25. D. A. Case, D. A. Pearlman, J. W. Caldwell, T. E. Cheatham, W. S. Ross, C. Simmerling, Y. Duan, J. Pitera, I. Massova, G. L. Seibel, U. C. Singh. P. Weiner, and P. A. Kollman. AMBER 6, University of California, San Francisco, CA 1999.
26. U. C. Singh and P. A. Kollman. An approach to computing electrostatic charges for molecules. J. Comput. Chem. 5:129-145 (1984).
27. M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, V. G. Zakrzewski, J. A. Montgomery, R. E. Stratmann. J. C. Burant, S. Dapprich, J. M. Millam, A. D. Daniels, K. N. Kudin, M. C. Strain, O. Farkas, J. Tomasi, V. Barone, M. Cossi, R. Cammi, B. Mennucci, C. Pomelli, C. Adamo, S. Clifford, J. Ochterski, G. A. Petersson, P. Y. Ayala. Q. Cui, K. Morokuma, D. K. Malick, A. D. Rabuck, K. Raghavachari, J. B. Foresman, J. Cioslowski, J. V. Ortiz, A. G. Baboul, B. B. Stefanov, G. Liu, A. Liashenko, P. Piskorz, I. Komaromi, R. Gomperts, R. L. Martin, D. J. Fox, T. Keith, M. A. Al-Laham, C. Y. Peng, A. Nanayakkara, C. Gonzalez, M. Challacombe, P. M. W. Gill, B. G. Johnson, W. Chen, M. W. Wong, J. L. Andres, M. Head-Gordon, E. S. Replogle, and J. A. Pople. Gaussian 98 Revision A.7, Gaussian, Inc, Wallingford, CT 1998.
28. H. Tsujishita and S. Hirono. CAMDAS: an automated conformational analysis system using molecular dynamics. J. Comput. Aided Mol. Des. 11:305-315 (1997).
29. T. A. Halgren. Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94. J. Comput. Chem. 17:490-519 (1996).
30. I. Muegge and Y. C. Martin. A general and fast scoring function for protein-ligand interactions: a simplified potential approach. J. Med. Chem. 42:791-804 (1999).
31. I. D. Kuntz, J. M. Blaney, S. J. Oatley, R. Langridge, and T. E. Ferrin. A geometric approach to macromolecule-ligand interactions. J. Mol. Biol. 161:269-288 (1982).
32. M. D. Eldridge, C. W. Murray, T. R. Auton, G. V. Paolini, and R. P. Mee. Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J. Comput. Aided Mol. Des. 11:425-445 (1997).
33. P. S. Charifson, J. J. Corkery, M. A. Murcko, and W. P. Walters. Consensus scoring: a method for obtaining improved hit rates from docking databases of three-dimensional structures into proteins. J. Med. Chem. 42:5100-5109 (1999).
34. R. D. Clark, A. Strizhev, J. M. Leonard, J. F. Blake, and J. B. Matthew. Consensus scoring for ligand/protein interactions. J. Mol. Graphics Mod 20:281-295 (2002).
35. W. L. Jorgensen, J. Chandrasekhar, J. D. Madura, R. W. Impey, and M. L. Klein. Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 79:926-935 (1983).
36. J. P. Ryckaert, G. Cicotti, and H. J. C. Berensden. Numerical integration of the Cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J. Comput. Phys. 23:327-341 (1977).
37. O. Gotoh. Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J. Biol. Chem. 267:83-90 (1992).
38. M. R. Wester, E. F. Johnson, C. Marques-Soares, P. M. Dansette, D. Mansuy, and C. D. Stout. Structure of a substrate complex of mammalian cytochrome P450 2C5 at 2.3 A resolution: evidence for multiple substrate binding modes. Biochemistry 42:6370-6379 (2003).
39. P. A. Williams, J. Cosme, A. Ward, H. C. Angove, D. M. Vinkovi, and H. Jhoti. Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature 424:464-468 (2003).